Responding to and managing antibiotic shortages: a qualitative study with experts and opinion leaders Authors: Vrinda Nampoothiri, Ritika Kondel Bhandari, Avaneesh Kumar Pandey, Oluchi Mbamalu, Jennifer Cohn, Sanjeev Singh, Marc Mendelson, Nusrat Shafiq, Esmita Charani, Bashar Haruna Gulumbe, Michael Samarkos, Enrico Baraldi, Michael Samarkos, ESMITA CHARANI, Bashar Haruna Gulumbe, ESMITA CHARANI, Enrico Baraldi, ESMITA CHARANI Published: 2025 ABSTRACT BackgroundWe investigated the main drivers for current shortages of licensed antibiotics, existing mitigation strategies undertaken and potential barriers in their implementation through in-depth interviews with experts operating in select regions.MethodsPurposive sampling was used to identify opinion leaders with expertise in managing antibiotic supply chains, access, and shortages between August 2023 and April 2024. Consented participants were interviewed using a semi-structured interview guide developed using the PESTELI (political, economic, sociological, ecological, technological, legal, industry) framework. Data collection and analysis were iterative and recursive, using constant comparison.ResultsParticipants who were interviewed (n=16) had local, national, and global roles in managing and studying access, supply, and demand chain management from Europe, South Africa, India and USA. Political engagement on antibiotic shortages is reported to facilitate effective mitigation strategies, especially in areas where there is strong evidence of government investment. Legal measures have also been used; for example, pharmacists in the UK being given rights to automatically substitute antibiotics on prescriptions and negotiating with pharmaceutical companies for greater transparency on the challenges in manufacturing. Economic incentives are currently missing and are recognised as being a driver for lack of engagement on this topic from pharmaceutical industry. Greater transparency is required from the pharmaceutical companies on the manufacturing chain issues that may lead to shortages. Technologically there is a major gap in systems to forecast and manage antibiotic shortages. Sociological elements include adopting appropriate communication to not cause panic buying and hoarding by organisations when there is an impending shortage. Legislative changes are linked to the political and economic barriers for cohesive systems to manage the antibiotic manufacture and supply chain in relation to shortages.ConclusionCurrently there are limited interventions to respond to and manage shortages. The antibiotic manufacture and supply chain is complex and under the influence of PESTELI indicators which will need to be understood and mitigated in different contexts and regions. Introduction Lack of antibiotic access and excess use remain important factors when considering the emergence and spread of bacterial antimicrobial resistance (AMR) 1– 3 . Optimising antibiotic use remains a priority in efforts to mitigate AMR, with countries agreeing to a series of commitments to reduce inappropriate antibiotic use at the second United Nations High Level Meeting on AMR in 2024 4 . Whilst evidence shows that there has been a 46% increase in the consumption of antibiotics worldwide from 2000 to 2018, lack of access to antibiotics when needed is a threat to safe and effective healthcare delivery particularly in populations in low- and middle-income countries (LMICs) 5 . Furthermore, whilst the lack of new products in the antibiotic development pipeline is of global concern 6 developing new antibiotics alone will not be enough. The lack of market incentives for new antibiotics is influencing the dry pipeline, and managing AMR is further compromised by the inequities in access to new agents, whereby populations in high income countries (HICs) often have easier and faster access than those in LMICs 7, 8 . Many new antibiotics approved between 2010 and 2020 are still not registered in the majority of LMICs, thereby limiting treatment options for antibiotic-resistant infections 7 . One reason could be the lack of sufficient local epidemiology data relating to bacterial resistance and antibiotic use. This challenges national programs in prioritising the introduction of new antibiotics or developing accurate forecasting models to predict demand, undermining efforts to support registration of new antibiotics. In view of the increasing antibiotic shortages, maintaining sustainable supply chains of quality-assured antibiotics is an objective of many AMR national action plans 9, 10 . The drivers for antibiotic shortages are complex. Low economic returns and/or limited size of the antibiotic manufacturing market have led to fewer supply chain actors. Manufacturing bottlenecks related to the migration of key producers of active pharmaceutical ingredients (API) to single or limited number of suppliers in India and China have further compromised this shrinking market 11 . At country level there are also regulatory and economic disincentives and lack of political engagement 11 . Responding to and managing antibiotic shortages requires a multifocal approach that includes regulatory, production, and supply chain measures. There also needs to be global co-operation that considers the contextual regulatory and economic environment of individual countries whilst managing a global shortages crisis 12 . Antibiotic shortages can adversely impact the emergence and spread of AMR through the use of alternative broader spectrum antibiotics or those less effective, which may result in higher costs and greater side effects 13 . Our recent systematic review on the causes and consequences of antibiotic shortages included 74 methodologically diverse studies 14 . The limited available evidence reports increased length of hospital stay and treatment failure due to using inferior alternative antibiotics during a shortage, and a negative impact on antimicrobial stewardship programmes (AMS), which must realign to the immediate impact of the shortages on institutional antibiotic prescribing patterns and infection management. There is no robust evidence linking shortages to AMR outcomes mainly due to lack of appropriately designed longitudinal studies. Where evidence of impact exists, it is predominantly from HICs (82.4%), indicating a large gap in the literature on the extent of and management of shortages in LMICs. Successful mitigation strategies reported in this review were driven by hospital AMS and infectious diseases teams. In this review, we focused on the USA, where most of the current evidence is generated, Europe, India, and South Africa, two countries with high antibiotic access and AMR challenges 14 . To explore the main drivers for current shortages of licensed antibiotics and existing mitigation strategies undertaken in different regions and potential barriers in their implementation, a situational analysis using key informant interviews with actors actively involved nationally and globally in antibiotic supply chain management was conducted. Considering the complexity of the actors and processes in antibiotic manufacturing and supply chains, we adopted a PESTELI (political, economic, sociological, ecological, technological, legal, industry) framework to provide a comprehensive overview and to understand the macro- environmental factors influencing shortages of licensed antibiotics and the ensuing mitigation strategies 15, 16 . Methods Study design and data collection Potential participants were purposively selected to identify those with expertise in antibiotic access and supply chains in HICs and LMICs. Experts were invited to participate in the study through email. Participation in the interview was voluntary. The global, contacted via email had roles at national and regional level across South Africa, Europe, India and USA. Those who agreed to be interviewed were recruited to the study. Written informed consent was obtained from all participants prior to the scheduled interviews. A piloted interview guide was used to conduct interviews face-to-face or on Zoom online platform. The interview guide was developed using the PESTELI framework. The interviews were scheduled at a date and time convenient for the participants. All the interviews were audio-recorded and transcribed verbatim. Due to the lack of evidence from the systematic review on the ecological impact of antibiotic shortages we did not explore this domain and allowed for the study participants to bring this up in the conversation. The study instruments, including interview guide, participant information leaflet and sample consent form are available online on Zivahub 17 . Data analysis Anonymised transcripts were thematically analysed aided by NVivo 12 software. A coding framework was created after analysing the first five transcripts and was refined by the authors as the coding progressed. Four researchers analysed the interviews independently of each other. Through regular meetings the analysis and framework were discussed and any questions regarding emerging themes were addressed. Data collection was iterative and recursive until thematic saturation was reached. Results Between August 2023 and April 2024, 16 opinion leaders with national, regional, and global roles in antibiotic supply chain management were interviewed. Table 1 gives the details of participants. Table 1. Details of interview participants analysing the current landscape in antibiotic access and supply.Participant IDCountryYears in practiceGenderSector of workScope of work and expertiseASouth Africa20MGlobal OrganisationGlobal supply chain managementBSouth Africa20MPublic Health Sector Regional and NationalGlobal supply chain managementCSouth Africa31FClinical Academic, Public Health Sector and Policy Non-Governmental OrganisationPolicy and Health, Access to medicines, including antibioticsDSweden25MAcademia and Industry Regional – European RegionAccess to medicines, including antibioticsEEuropean Union3MAcademia and Industry Regional – European RegionInnovation and access of medicines, including antibiotics in the European UnionFSouth Africa36FPublic Sector and Industry NationalAntimicrobial stewardship and antibiotic shortages and access managementGSouth Africa43MAcademic National CommitteePharmacology and Pharmacovigilance and National level mitigation of drug shortagesHSouth Africa-FClinical Academic Public Health SectorAntimicrobial stewardship and accessISouth Africa-MNon-Governmental Organisation National and RegionalManagement of availability and shortages of medicinesJSouth Africa-FProvincial Health Management Public Health SectorHospital Pharmacy ManagementKUK30MNational Public Health and PolicyManagement of UK supply chain, AMR, antimicrobial stewardshipLSweden20MClinical Academic linked to Industry, Public Health and Policy National and Regional- European RegionResearcher working in the field of AMR and antibiotic accessMUK17MNational Public Health and PolicyAntibiotic prescribing and dose optimisation in field of AMR, Medicine optimizationNUS8MNational Public Health and PolicyExperience on developing standards for ensuring quality of medicines, policy levels, Supply chain managementOUK-MNational Public Health and PolicyEconomic burden of antimicrobial resistancePIndia15MAcademia and Industry National and RegionalNew Entry Antibiotics Deal in patent filing from industry and academia, introduction of new antibiotics to the market Supply Chains Details of interview participants analysing the current landscape in antibiotic access and supply. Characteristics of antibiotic manufacture and procurement in different countries One of the key factors that emerged was differences in antibiotic procurement models between countries and how this may impact the extent of and response to antibiotic shortages. India together with China is one of the main manufacturers and suppliers of antibiotic APIs, a duopoly that can impact global API availability. There is no global procurement model, with countries having their own procurement strategies and processes for all medicines. There are also differences between private and public sectors within countries and by region. Participants considered pooled procurement across countries as a possible solution to manage the supply of antibiotics wherein countries co-operate to decide on a portfolio of antibiotics and other medications, which would allow them to negotiate a fair market price with the manufacturers (Q1, Table available online on Zivahub 17 ). There was also a recognition of the need for greater transparency in the antibiotic manufacturing and supply chain by pharmaceutical companies (Q2, online Table) 17 . As the clinical experience of the participants were from South Africa, India, UK, Sweden and the USA, we use these five countries procurement systems as case-studies in managing and responding to shortages of licensed antibiotics and their short-term and long-term impacts Table 2. Table 2. Summary of current systems related to antibiotic shortages including health system, procurement, alert and response systems in the countries of included in this study.CountryImport versus export index of antibioticsPublic versus private proportion of healthcareExisting procurement strategies e.g. whether national or regionalPolicy and governance in place around managing shortagesCurrent nationally available data resources on status of or respond to shortagesIndiaExport more than import (one of the largest producers of antibiotics)Public sector hospitals account for 10% of hospitals in the countryProcurement occurs at national, federal, state, local government and autonomous body level. Contractual conditions vary and manufacturers bid for contracts at the various levelsShortages in hospitals in case of outbreaks are often managed by the private pharmacies.Currently, the shortages are only reported through a website Organisation of Pharmaceutical producers of India (OPPI). However, there is lack of data harmonisation across manufactures and hospitals, which can effectively lead to mitigation of shortages reportedSouth AfricaImport more that exportPublic sector serves 84% of the populationProvincial-level tender system, whereby the price of medicines is set and complied to in the tender. Secondary suppliers fill the gaps in drug stock outsLocally hospitals develop policies and manage shortages as part of stewardship programmes. In the Western Cape province, the provincial offices respond to and manage shortages by collaborating with specialist groups within their provincial AMS committee to develop alternative therapies. Ledgers are maintained to keep three-month stockholding for the antibiotics as their uptake volume is large. When options are exhausted, public hospitals (which cater to majority of the population) reach out to the private sector.There is a lack of a national database or antibiotic shortages reporting system in the countrySwedenImport more than exportHealthcare in Sweden is decentralised, 100% public sector, lies with the regional councils and, in some cases, local councils or municipal governmentsThere are few pharmaceutical companies that sell generic antibiotics with one company responsible for more than 50% of market sales. In 2023, the Government commissioned the Public Health Agency of Sweden to carry out a preliminary study of a new reimbursement model where pharmaceutical companies receive compensation for providing a buffer stock of certain prioritised off- patent antibioticsThree agencies are involved in governance to manage shortages: reimbursement agency, Public Health Agency, the Medical Product Agency, equivalent to the USA Food and Drug Agency (FDA) or European Medicines Agency (EMA). Among these, the Public Health Agency has a unique role in engaging openly with the industry regarding shortages. They organize workshops, facilitate discussions, and have spearheaded innovative reimbursement modelsThe Public Health Agency of Sweden (PHAS) of Sweden has established policies for managing antibiotic shortages. PHAS has been tasked with proposing and piloting models to ensure the availability of approved antibiotics, aiming to combat antibiotic resistance as part of a broader public health strategyUKImport more than exportThe UK has a 100% public sector by government- sponsored universal healthcare system called the National Health Service (NHS). Private sector healthcare system is voluntary for rapid access to elective care and other services.the Department of Health and Social Care (DHSC) is responsible for ensuring a stable supply of antibiotics across the country. For patented branded medicines, pharmaceutical companies agree a fixed price with manufacturers to secure supply. For generic antibiotics, however, the supply chain is managed through three distinct contracted areas based on geographic regions, with two-year rolling cycles to maintain consistent availability across the nation.In case of shortages, Department of Health in the UK leads on supply chain for primary care, whereas NHS England work for leads on supply chain for hospitals.There is a national dashboard in Department of Health and social care where upcoming shortages and stock-outs are reported. The Department releases guidance on national shortage antibiotics to advise on alternative therapiesUSAImport more than exportHospitals are largely (80%) operated in the private sectorSubscription Models involve fixed payments to pharmaceutical companies for access to antibiotics, which may include provisions for both fixed and volume- based components of payment. Pooled Procurement Models consolidates purchasing power among healthcare providers or systems to negotiate better prices and terms for antibiotics.There is an essential medicine list from which vulnerable medicines (those at increased risk of being affected by shortages) are selected for local manufacture. Some key reasons to categorise a medicine as vulnerable include geographic concentration, complexity of manufacturing the medicine, quality testing issues, and price.The FDA gathers data on medicine shortages in the country including antibiotics. The Academy of Health Systems Pharmacists hosts a resource page for drug shortages, with self-reported data by pharmacists. As of 30 September 2024, there were 41 active antimicrobial shortages reported in the USA. The data on these resources, however, are limited to notice of a shortage and an expected end date. There are no data on policy or formulary change recommendations, mitigation strategies at healthcare system level or a report of consequences of these shortages. Summary of current systems related to antibiotic shortages including health system, procurement, alert and response systems in the countries of included in this study. Causes of antibiotic shortages Causes for antibiotic shortages reported by study participants ranged from concentration of API manufacturing in only a few countries to lack of adequate forecasting from manufacturers and lack of strict regulations at government level. The key causes for antibiotic shortages as informed by the interview participants is illustrated in Figure 1. Key causes of antibiotic shortages as reported by the study participants mapped to the political, economic, sociological and ecological, technological, legal, and pharma industry (PESTELI) framework. The individual elements of the PESTELI framework which play roles in the antibiotic manufacturing, procurement and management of antibiotic shortages which were discussed during the interviews are described in the sections below. Political, policy, and legal frameworks within context of countries Participants agreed that prioritisation of antibiotic shortages by governments is beneficial especially in developing and implementing guidelines for alternative antibiotics (Q3, online table) 17 . Participants from the UK identified the Department of Health and the NHS leadership as playing a role in managing shortages and that there are communication mechanisms between them and subject matter experts to assess the impact of shortages on clinical and patient outcomes (Q4, online table) 17 . In Sweden, there are government-assigned authorities, such as the Medical Products Agency, that work on antibiotic availability and develop strategies to mitigate any immediate or future shortages (Q5, online table) 17 . However, the lack of effective and easily accessible communication from the government has been highlighted by participants from South Africa (Q6, online table) 17 . As only China and India predominantly control API supply, participants considered that during shortages API supply to countries that produce higher profit margins may be prioritized, to the disadvantage of other countries. Additionally, incorrect national estimates and delayed provincial payments hinder the ability to maintain sufficient buffer stock, exacerbating supply issues. In South Africa participants highlighted that shortages may be caused by contractual transition between suppliers where one supplier scales down and does not fulfil their orders towards the end of their contract, while the new supplier takes longer to begin production (Q7, online table) 17 . In the USA, whilst government is invested in supporting gathering of basic data on medicines shortages, current resources do not allow for sufficient data to be gathered that can help better understand the causes and consequences to better inform policy and practice (Q8, online table) 17 . Economic factors Participants agreed that the pricing of antibiotics plays a role in shortages. Price capping is considered not viable, incompatible with current market prices, and a potential driver of shortages (Q9, online table) 17 . Successive budget cuts in hospitals can also impact the stocks held in the pharmacies, reducing the buffer stock that could have prevented shortages (Q10, online table) 17 . Optimal use of the manufacturing capacity is important since limited use of capacity can result in increased antibiotic production costs (Q11, online table) 17 . Due to the low profitability of the market and low return of investments, suppliers are pulling out of market which could result in antibiotic shortages especially if there is no innovator brand (Q12, online table) 17 . When prices are low, drug sales need to increase to maintain profitability. Having only a few suppliers producing large volumes of an antibiotic can also lead to shortages (Q13, online table) 17 . Low profit margin for generic antibiotics is a market force driving lack of investment. The high pressure on lowering the cost of generic antibiotics has resulted in increasing numbers of generic manufacturers leaving the field or focusing on those antibiotics which remain profitable (Q14, online table) 17 . In the European Union, pull incentives schemes such as the Swedish model aims to generate additional manufacturer revenue to maintain the supply chain of five selected antimicrobials. (Q15, online table) 17 . The minimal economic incentives for pharmaceutical industry to manufacture antibiotics has resulted in financial strains for many companies. They are also disincentivised to sell antibiotics in those countries where they would lose money selling antibiotics. Solutions to managing shortages may also have economic consequences. A potential economic approach that may offer insights is the US Presidency Emergency Plan for AIDS Relief (PEPFAR) model which supports countries to locally produce antiretrovirals, expanding local pharmaceutical production capabilities as well as procurement 18 . This option, however, relies on NGO commitment, is costly to governments, and may be therefore have its limitations. The other model is when there is an intermediary between manufacturers and national procurers who purchases the drugs and sells them (Q16, online table) 17 . Sociological factors Antibiotic shortages result in delays in treatment, in addition to patients having to purchase antibiotics with higher costs and adverse effects (Q17, online table) 17 . This is of significant consequence to paediatric patients due to limited alternative formulations (Q18, online table) 17 . These could be contributing factors to the emergence of AMR in the long run. Availability of information to the public regarding antibiotic shortages was considered to have positive and negative consequences in relation to demand for antibiotics. A lack of sufficient information provided to patients on antibiotic use could increase demand for antibiotics, particularly in countries without universal healthcare coverage (Q19, online table) 17 , whereas in countries with universal healthcare coverage the opposite may occur (Q20, online table) 17 . Appropriate education on antibiotic use ideally is needed from school age, customised for the different age groups and target population literacy levels (Q21, 22, online table) 17 . This highlights the differences in populations across and within countries in terms of access to resources that benefit health, and health beliefs and practices. Participants also informed that hoarding leftover medicines for future use because of difficulty in accessing healthcare may be practiced, particularly from community pharmacies (Q23, online table) 17 . Social media was recognized as having a role in encouraging the public to hoard medicines especially when there is a shortage (Q24, online table) 17 . Better communication is also important between suppliers and hospitals to ensure that sufficient stocks are available (Q25, online table) 17 . Mitigation strategies in South Africa include moving stocks between facilities with involvement of the pharmacy and therapeutics committee and AMS teams in hospitals to advise prescribers on alternatives (Q26, online table). Technological factors The need for available technology to provide information on antibiotic procurement, supply, and shortages was recognised by participants. It is important to have a mechanism to track indicators of shortages in real time, which can be used to predict shortages that will enable better management. Implementation and adoption of such of technologies is inconsistent. In the UK, communication of antibiotic shortages is such that sufficient information is provided so that the people can be prepared without resulting in increased demand (Q27, online table). The public have access to an app from where they can see the medicine stocks and the nearest pharmacy where they would be available (Q28, online table) 17 . There is also a bulletin, which provides real-time data on shortages and any supply chain issues wherein the healthcare providers can log in and see how long a shortage is going to last and what are the alternatives available for the medicine in shortage. Additionally, a medicine supply notification system alerts hospital and community pharmacies to shortages providing a description of the shortage along with its durations and available alternatives (Q29, online table) 17 . Another strategy adopted in the UK was implementing a dashboard to provide live dispensing data thereby enabling forecast of how many days of stock is left (Q30, online table). In many countries, including Sweden, healthcare institutions do not use automated information systems for procurement and prescribing, leading to a lack of data linkage for information sharing and longitudinal assessment of supply patterns and any interruptions to the supply of medicines including antibiotics (Q31, online table) 17 . The Medical Product Agency has built a national system to track the availability of antibiotics wherein registered users, predominantly prescribers, can log in and check availability of specific antibiotics. The system however is not widely adopted. In response to this, currently efforts are in place to build a system that will allow prescribers to see the availability of the antibiotic when they prescribe it (Q32, online table) 17 . Organisations such as Indian Drug Manufacturers Association (IDMA) and Organisation of Pharmaceutical Producers of India (OPPI) enable pharmaceutical manufacturers to register and maintain a consolidated database, which can be accessed upon request during shortages (Q33, online table) 17 . In South Africa there is a stock visibility system, however, there too the technology fails to link provincial and national databases, and overall, negates any benefit of the alert system (Q34, online table) 17 . USA has implemented the medicines supply chain map that includes data of manufacturing of all drugs that is being supplied to the USA. This data can indicate and quantify shortages in categories (Q35, online table) 17 . Legal factors and frameworks Many of the HICs have poorly enforced regulations in place that mandate pharmaceutical companies to alert healthcare systems to the likelihood or risk of upcoming drug shortages. If implemented effectively such legal mandates may lead to more consistent data on antibiotic shortages. Because where such legislation does exist it is predominantly in HICs, this may mean that at an international level, what gets prioritised in terms of response to antibiotic supply issues is often driven by HIC needs, whilst the impact of AMR and antibiotic shortages are invariably more pronounced In LMICs (Q36, online table) 17 . In Europe, the European commission is responsible for improving innovation and access to medical countermeasures and is responsible for dealing with disruption the antibiotic supply chain (Q37, online table) 17 . The ‘serious shortages protocol’, a legal instrument available in the UK allows pharmacists to dispense alternative antibiotics without consulting the prescriber during an antibiotic shortage (Q38, online table) 17 . The Department of Health and Social Care has legal responsibility for ensuring that medicines are available in the country and that manufacturers report a shortage or expectation of one, directly to the Department of Health (Q39, online table) 17 . While this system has strengths such as good communication and awareness around antibiotic shortages, its weakness lies in the lack of real-time information on stock holdings and community pharmacies across the country (Q40, online table) 17 . The USA, Canada and Australia have similar legal requirements, but this may not be the case in LMICs. Industry factors By and large, the role of industry is absent as an active partner in working to mitigate shortages. Hospital pharmacists in South Africa through their supplier networks are likely to be informed of impending antibiotic shortages in an ad-hoc fashion, with no formal mechanism of communication between pharmaceutical manufacturers and the Department of Health (Q41, online table) 17 . In the UK, there is a legal requirement wherein the manufacturers need to notify the Department of Health in case of any shortages (Q42, online table) 17 . Monopolisation of API production by a few countries like India and China was reported as a challenge particularly if production is impacted (Q43, online table) 17 . Participants also reported problems with ensuring the quality of the products received, especially since organisations like the South African Health Product Regulatory Authority (SAHPRA) monitors the testing facilities but does not conduct quality tests of the products (Q44, online table) 17 . In addition to the mitigation strategies elaborated in the above sections, participants also provided some potential strategies to better handle situations of antibiotic shortages. We have stratified these by government, pharmaceutical industry, hospital and patient and public sector levels, shown in Figure 2. Potential mitigation strategies for forecasting, responding to and managing antibiotics shortages from the macro to meso level. Discussion This study used key informant interviews to explore the main drivers for current shortages, existing mitigation strategies undertaken in different regions and potential barriers in their implementation using a PESTELI framework. A key contributing factor to antibiotic shortages suggested by the participants was the duopoly of antibiotic supply from India and China, which risks production and global supply chain disruption 19 . Study participants recommended using a pooled procurement system for antibiotics, which would allow negotiation of a fair price with manufacturers. The systematic review by Parmaksiz et al., on pooled procurement of medicines and vaccines recommends that this mechanism can result in lower prices, increased availability, higher quality and more efficient procurement processes 20 . Berman and colleagues also recommend the adoption of an antimicrobial subscription and pooled procurement model, anchored by regional market leaders and guaranteeing public and private sector access to antimicrobials 21 . The low profitability of the antibiotics has resulted in suppliers leaving the market. Whilst there are pull incentives in place in many countries, little attention has been paid to finance of these incentives 22 . In LMICs, weak laboratory capacity, lack of health information systems, and limited resources results in low quality data, which does not show the actual scenario of AMR in these countries 23 . In many LMICs, access to antibiotics is poor but inappropriate use reduces supply further. For example, in India, a country with high burden of infectious diseases and poorly regulated access to antibiotics, a lack of community-level antibiotic stewardship leads to excess use 24 . HICs also have stricter reporting of shortages. Registries for pharmaceutical companies to report upcoming shortages and their estimated duration are a vital tool to enable a quick response from the government 13 . Government and subject-matter experts in the UK collaborate to assess the impact of shortages on clinical and patient outcomes. Governments also work with pharmaceutical companies to review stockpiling policies to ensure sufficient stocks anticipating imbalances between supply and demand 25 . AMS initiatives and effective communication between physicians, pharmacists, and stockists is recommended as an effective strategy to mitigate antibiotic shortages 12 . Participants in our study also suggested that structured communication should also be provided to patients and public, which could result in a decrease in unnecessary antibiotic demand from their end. Direct patient counselling by healthcare provider and printed education material can reduced antibiotic use 26 . Whilst the majority of the national action plans emphasise public education as a means for raising awareness on AMR, only limited strategies have been identified in these plans to achieve this awareness 9 . Age-appropriate education on antibiotic use should be initiated in schools and there should be more funding provided for conducting community engagement activities on AMR especially in LMICs with unregulated access to antibiotics. Limitations of the study We were interested in exploring the antibiotic shortages in India in detail, however, despite inviting many potential participants, only one consented to being interviewed. We reached out to potential participants from the pharmaceutical industries in different countries to contribute to the learning in this study, but due to employment clauses and confidentiality we could not interview them. Despite these limitations, the study provides a detailed presentation of the key factors that play a role in antibiotic shortages in different countries and contexts. The ecological implications of antibiotic shortages did not emerge from these interviews. Based on our existing work and the systematic review we have undertaken this aspect remains unexplored. The migration of major API producers to two countries and the process of manufacturing of antibiotics and treatment of waste materials may have implications for those populations and this is something that needs to be studied. Conclusion This study shows that the causes of antibiotic shortages are multi factorial and requires interdisciplinary mitigation strategies. Currently there are limited interventions to respond to and manage shortages. The antibiotic manufacture and supply chain is complex and under the influence of various PESTELI indicators which will need to be understood and managed in different contexts and regions. Better understanding the complex factors contributing to antibiotic shortages will support development and adoption of mitigation strategies and tools for forecasting shortages and their optimised management. Different actors at the government, healthcare, pharmaceutical industry and public levels should work together to manage antibiotic use and shortages. In addition, it is important that the strategies developed are contextually fit after critically assessing the existing local demand and supply chains within countries and the political, legislative, and economic incentives for effective participation of all actors concerned. Ethics approval and consent to participate Institutional approval to conduct the study was provided by the human research ethics committees (HREC) of the University of Cape Town (UCT), South Africa (UCT HREC: 488/2022) and Amrita Institute of Medical Sciences, Kochi, Kerala, India (IEC-AIMS-2022-MEDADN-164). Written informed consent was obtained from all participants prior to interview. The authors have addressed my concerns. I have no further comments. Is the work clearly and accurately presented and does it cite the current literature? Partly If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Is the study design appropriate and is the work technically sound? Partly Are the conclusions drawn adequately supported by the results? Partly Are sufficient details of methods and analysis provided to allow replication by others? Yes Reviewer Expertise: Antimicrobial resistance, microbial ecology, environmental microbiology, omics, and antimicrobial stewardship. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. I have read the revised manuscript and the authors' responses to my comments. I am satisfied with the changes made to the manuscript. Is the work clearly and accurately presented and does it cite the current literature? Yes If applicable, is the statistical analysis and its interpretation appropriate? Not applicable Are all the source data underlying the results available to ensure full reproducibility? Yes Is the study design appropriate and is the work technically sound? Yes Are the conclusions drawn adequately supported by the results? Partly Are sufficient details of methods and analysis provided to allow replication by others? Partly Reviewer Expertise: Antimicrobial resistance, antimicrobial stewardship I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Thanks for the opportunity to reassess this work. I am pleased to see that the authors have implemented basically all my suggestions. Therefore, from my perspective the paper is now ready for final acceptance. Is the work clearly and accurately presented and does it cite the current literature? Yes If applicable, is the statistical analysis and its interpretation appropriate? Not applicable Are all the source data underlying the results available to ensure full reproducibility? Yes Is the study design appropriate and is the work technically sound? Yes Are the conclusions drawn adequately supported by the results? Partly Are sufficient details of methods and analysis provided to allow replication by others? Yes Reviewer Expertise: NA I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Responding to and managing antibiotic shortages: a qualitative study with experts and opinion leaders (Wellcome Open Research 2025, 10:347 ) SUMMARY OF THE ARTICLE This is a qualitative research study investigating how different countries respond to and manage antibiotic shortages. It should be made clear that the study is based on interviews with experts in managing antibiotic supply chains, rather than facts collected by the authors themselves. The authors used purposive sampling of experts in the field and conducted semi-structured interviews which they analyzed with specialized software. The interviews were structured using the PESTELI (political, economic, sociological, technological, legal, industry) framework, thus the results are similarly provided using the same framework. The results are divided into: Characteristics of antibiotic manufacture and procurement in different countriesCauses of antibiotic shortagesFactors affecting antibiotic manufacturing, procurement and managing antibiotic shortage (reported per individual element of the PESTELI framework)Mitigation strategies for antibiotic shortages The results are generally presented clearly, and the authors provide useful graphical summaries of the key causes of antibiotic shortages and of mitigation strategies. Characteristics of antibiotic manufacture and procurement in different countries Characteristics of antibiotic manufacture and procurement in different countries Causes of antibiotic shortages Causes of antibiotic shortages Factors affecting antibiotic manufacturing, procurement and managing antibiotic shortage (reported per individual element of the PESTELI framework) Factors affecting antibiotic manufacturing, procurement and managing antibiotic shortage (reported per individual element of the PESTELI framework) Mitigation strategies for antibiotic shortages Mitigation strategies for antibiotic shortages SPECIFIC QUESTIONS Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Partly. There is room for improvement, especially regarding the sampling process: The authors should provide details for the recruitment rationale and for the experts mix, report invitations to experts, non-responses etc.Providing a thematic saturation grid might be useful.I would suggest that the authors provide information on study conformation with the existing standards for reporting qualitative research (SRQR, COREQ etc) If applicable, is the statistical analysis and its interpretation appropriate? Not applicable. Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Mostly yes, but key findings should be set out more clearly. Is the study design appropriate and is the work technically sound? Yes Is the study design appropriate and is the work technically sound? Yes Yes Yes Are sufficient details of methods and analysis provided to allow replication by others? Partly. There is room for improvement, especially regarding the sampling process: The authors should provide details for the recruitment rationale and for the experts mix, report invitations to experts, non-responses etc.Providing a thematic saturation grid might be useful.I would suggest that the authors provide information on study conformation with the existing standards for reporting qualitative research (SRQR, COREQ etc) Are sufficient details of methods and analysis provided to allow replication by others? Partly. There is room for improvement, especially regarding the sampling process: The authors should provide details for the recruitment rationale and for the experts mix, report invitations to experts, non-responses etc.Providing a thematic saturation grid might be useful.I would suggest that the authors provide information on study conformation with the existing standards for reporting qualitative research (SRQR, COREQ etc) Partly. There is room for improvement, especially regarding the sampling process: The authors should provide details for the recruitment rationale and for the experts mix, report invitations to experts, non-responses etc. Partly. There is room for improvement, especially regarding the sampling process: The authors should provide details for the recruitment rationale and for the experts mix, report invitations to experts, non-responses etc. Providing a thematic saturation grid might be useful. Providing a thematic saturation grid might be useful. I would suggest that the authors provide information on study conformation with the existing standards for reporting qualitative research (SRQR, COREQ etc) I would suggest that the authors provide information on study conformation with the existing standards for reporting qualitative research (SRQR, COREQ etc) If applicable, is the statistical analysis and its interpretation appropriate? Not applicable. If applicable, is the statistical analysis and its interpretation appropriate? Not applicable. Not applicable. Not applicable. Are all the source data underlying the results available to ensure full reproducibility? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Yes Yes Are the conclusions drawn adequately supported by the results? Mostly yes, but key findings should be set out more clearly. Are the conclusions drawn adequately supported by the results? Mostly yes, but key findings should be set out more clearly. Mostly yes, but key findings should be set out more clearly. Mostly yes, but key findings should be set out more clearly. COMMENTS In the introduction the authors stress the role of antibiotic shortages in AMR development, however they offer few insights into this issue thereafter. In the Results section, AMR is only mentioned once (in the Legal factors subsection). The title of the manuscript refers to “responses and management of antibiotic shortages”, but in the last paragraph of the Introduction the authors also state that “exploring the main drivers” was also an aim of the study. Exploring the drivers of shortages themselves is quite complex, as the causes (and the management) differ depending on the level of shortages i.e., local, national or global. It, therefore, seems to me that this study has too broad a scope. I am not sure that all these issues can be covered adequately. I suggest that the authors focus more on national or global shortages. The breadth of scope may cause issues. E.g. in p 8, subsection “Sociological factors” the authors initially discuss some effects of antibiotic shortages (“Antibiotic shortages result in delays in treatment, in addition to patients having to purchase antibiotics etc”), which is not relevant there. Participants imbalance is an important issue. 8/16 experts are from South Africa, while there is only one expert from India and none from China (which are the two major producers of API). This creates imbalance in the results as e.g. in South Africa 84% of healthcare is covered by the public sector. Consequently, although thematic saturation might have been reached, the responses would cover much more the problems of the public rather than private sector. The authors acknowledged some but not all of these issues in the limitations (e.g not explanation for the lack of participants from China). Is the work clearly and accurately presented and does it cite the current literature? Yes If applicable, is the statistical analysis and its interpretation appropriate? Not applicable Are all the source data underlying the results available to ensure full reproducibility? Yes Is the study design appropriate and is the work technically sound? Yes Are the conclusions drawn adequately supported by the results? Partly Are sufficient details of methods and analysis provided to allow replication by others? Partly Reviewer Expertise: Antimicrobial resistance, antimicrobial stewardship I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Comment: This is a qualitative research study investigating how different countries respond to and manage antibiotic shortages. It should be made clear that the study is based on interviews with experts in managing antibiotic supply chains, rather than facts collected by the authors themselves. The authors used purposive sampling of experts in the field and conducted semi-structured interviews which they analyzed with specialized software. The interviews were structured using the PESTELI (political, economic, sociological, technological, legal, industry) framework, thus the results are similarly provided using the same framework. The results are divided into: Characteristics of antibiotic manufacture and procurement in different countriesCauses of antibiotic shortagesFactors affecting antibiotic manufacturing, procurement and managing antibiotic shortage (reported per individual element of the PESTELI framework)Mitigation strategies for antibiotic shortages The results are generally presented clearly, and the authors provide useful graphical summaries of the key causes of antibiotic shortages and of mitigation strategies. Response The authors thank the reviewer for highlighting the relevance of the study. Comment Specific questions: Are sufficient details of methods and analysis provided to allow replication by others? Partly. There is room for improvement, especially regarding the sampling process: The authors should provide details for the recruitment rationale and for the experts mix, report invitations to experts, non-responses etc.Providing a thematic saturation grid might be useful.I would suggest that the authors provide information on study conformation with the existing standards for reporting qualitative research (SRQR, COREQ etc) Response: For qualitative research we do not usually provide non-respondent data. We have now provided the rationale for the recruitment and the limitations section does provide details on the implications of this strategy. Characteristics of antibiotic manufacture and procurement in different countries Characteristics of antibiotic manufacture and procurement in different countries Causes of antibiotic shortages Causes of antibiotic shortages Factors affecting antibiotic manufacturing, procurement and managing antibiotic shortage (reported per individual element of the PESTELI framework) Factors affecting antibiotic manufacturing, procurement and managing antibiotic shortage (reported per individual element of the PESTELI framework) Mitigation strategies for antibiotic shortages Mitigation strategies for antibiotic shortages Partly. There is room for improvement, especially regarding the sampling process: The authors should provide details for the recruitment rationale and for the experts mix, report invitations to experts, non-responses etc. Partly. There is room for improvement, especially regarding the sampling process: The authors should provide details for the recruitment rationale and for the experts mix, report invitations to experts, non-responses etc. Providing a thematic saturation grid might be useful. Providing a thematic saturation grid might be useful. I would suggest that the authors provide information on study conformation with the existing standards for reporting qualitative research (SRQR, COREQ etc) I would suggest that the authors provide information on study conformation with the existing standards for reporting qualitative research (SRQR, COREQ etc) Comment: In the introduction the authors stress the role of antibiotic shortages in AMR development, however they offer few insights into this issue thereafter. In the Results section, AMR is only mentioned once (in the Legal factors subsection). The title of the manuscript refers to “responses and management of antibiotic shortages”, but in the last paragraph of the Introduction the authors also state that “exploring the main drivers” was also an aim of the study. Exploring the drivers of shortages themselves is quite complex, as the causes (and the management) differ depending on the level of shortages i.e., local, national or global. It, therefore, seems to me that this study has too broad a scope. I am not sure that all these issues can be covered adequately. I suggest that the authors focus more on national or global shortages. Response: The aim of the paper has been modified to a situational analysis using key informant interviews with actors actively involved, nationally and globally, in antibiotic supply chain management to explore the main drivers for current shortages, existing mitigation strategies undertaken in different regions and potential barriers in their implementation. Comment: The breadth of scope may cause issues. E.g. in p 8, subsection “Sociological factors” the authors initially discuss some effects of antibiotic shortages (“Antibiotic shortages result in delays in treatment, in addition to patients having to purchase antibiotics etc”), which is not relevant there. Response: We had added this point to show link between antibiotic shortages and AMR especially in pediatric population. We have modified the point to further clarify this (line 344) Comment: Participants imbalance is an important issue. 8/16 experts are from South Africa, while there is only one expert from India and none from China (which are the two major producers of API). This creates imbalance in the results as e.g. in South Africa 84% of healthcare is covered by the public sector. Consequently, although thematic saturation might have been reached, the responses would cover much more the problems of the public rather than private sector. The authors acknowledged some but not all of these issues in the limitations (e.g not explanation for the lack of participants from China). Response: Participation in the interview was voluntary. We reached out to stakeholders in South Africa, Europe, India and USA and interviewed those participants who consented. This paper seeks to address the important topic of antibiotic shortages and the challenges they create for healthcare systems and antimicrobial stewardship. The authors explore these issues using expert interviews framed through the PESTELI lens. The subject matter is highly relevant, and the need to better understand supply chain vulnerabilities is clear. However, after careful consideration, I have significant concerns about the strength of the evidence and the scope of the conclusions that are drawn as follows: The study does not directly contribute to our understanding of the drivers of antimicrobial resistance. Shortages may certainly contribute indirectly, through inappropriate substitutions or the use of broader spectrum agents, but this study does not present empirical data linking shortages to resistance outcomes. The framing of shortages as a driver of resistance is therefore stronger than the evidence allows.The evidence base is also limited. Sixteen expert interviews across five countries provide useful perspectives, but the sample is heavily weighted toward South Africa and high income settings. Large regions such as Latin America, much of Africa, and Southeast Asia are missing, and perspectives from the pharmaceutical industry are largely absent. This limits the ability to generalise the findings or present them as a global picture.The PESTELI framework offers structure for analysis, but the study remains descriptive and exploratory. Some of the conclusions read as prescriptive and definitive when they should be framed more cautiously. In addition, the ecological dimension of shortages was not explored, despite its importance in antibiotic manufacturing and the potential link to antimicrobial resistance in the environment.Another issue is novelty. The authors recently published a systematic review on antibiotic shortages, and the present work risks being seen as incremental rather than substantially new. The overlap between the two outputs should be made very clear. On balance, I believe the paper has potential value as a situational analysis of supply chain perspectives, but in its current form it does not make a sufficiently strong or novel contribution to merit indexing. The study does not directly contribute to our understanding of the drivers of antimicrobial resistance. Shortages may certainly contribute indirectly, through inappropriate substitutions or the use of broader spectrum agents, but this study does not present empirical data linking shortages to resistance outcomes. The framing of shortages as a driver of resistance is therefore stronger than the evidence allows. The study does not directly contribute to our understanding of the drivers of antimicrobial resistance. Shortages may certainly contribute indirectly, through inappropriate substitutions or the use of broader spectrum agents, but this study does not present empirical data linking shortages to resistance outcomes. The framing of shortages as a driver of resistance is therefore stronger than the evidence allows. The evidence base is also limited. Sixteen expert interviews across five countries provide useful perspectives, but the sample is heavily weighted toward South Africa and high income settings. Large regions such as Latin America, much of Africa, and Southeast Asia are missing, and perspectives from the pharmaceutical industry are largely absent. This limits the ability to generalise the findings or present them as a global picture. The evidence base is also limited. Sixteen expert interviews across five countries provide useful perspectives, but the sample is heavily weighted toward South Africa and high income settings. Large regions such as Latin America, much of Africa, and Southeast Asia are missing, and perspectives from the pharmaceutical industry are largely absent. This limits the ability to generalise the findings or present them as a global picture. The PESTELI framework offers structure for analysis, but the study remains descriptive and exploratory. Some of the conclusions read as prescriptive and definitive when they should be framed more cautiously. In addition, the ecological dimension of shortages was not explored, despite its importance in antibiotic manufacturing and the potential link to antimicrobial resistance in the environment. The PESTELI framework offers structure for analysis, but the study remains descriptive and exploratory. Some of the conclusions read as prescriptive and definitive when they should be framed more cautiously. In addition, the ecological dimension of shortages was not explored, despite its importance in antibiotic manufacturing and the potential link to antimicrobial resistance in the environment. Another issue is novelty. The authors recently published a systematic review on antibiotic shortages, and the present work risks being seen as incremental rather than substantially new. The overlap between the two outputs should be made very clear. Another issue is novelty. The authors recently published a systematic review on antibiotic shortages, and the present work risks being seen as incremental rather than substantially new. The overlap between the two outputs should be made very clear. Is the work clearly and accurately presented and does it cite the current literature? Partly If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Is the study design appropriate and is the work technically sound? Partly Are the conclusions drawn adequately supported by the results? Partly Are sufficient details of methods and analysis provided to allow replication by others? Yes Reviewer Expertise: Antimicrobial resistance, microbial ecology, environmental microbiology, omics, and antimicrobial stewardship. I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above. Comment: This paper seeks to address the important topic of antibiotic shortages and the challenges they create for healthcare systems and antimicrobial stewardship. The authors explore these issues using expert interviews framed through the PESTELI lens. The subject matter is highly relevant, and the need to better understand supply chain vulnerabilities is clear. However, after careful consideration, I have significant concerns about the strength of the evidence and the scope of the conclusions that are drawn as follows: Response: We have responded to your comments below. Comment: The study does not directly contribute to our understanding of the drivers of antimicrobial resistance. Shortages may certainly contribute indirectly, through inappropriate substitutions or the use of broader spectrum agents, but this study does not present empirical data linking shortages to resistance outcomes. The framing of shortages as a driver of resistance is therefore stronger than the evidence allows. Response: The aim of the study was to conduct a situational analysis using key informant interviews with actors actively involved, nationally and globally, in antibiotic supply chain management to explore the main drivers for current shortages, existing mitigation strategies undertaken in different regions and potential barriers in their implementation. We intended to show the complexity of the issue and highlight the need for an interdisciplinary approach to mitigate antibiotic shortages. Comment: The evidence base is also limited. Sixteen expert interviews across five countries provide useful perspectives, but the sample is heavily weighted toward South Africa and high-income settings. Large regions such as Latin America, much of Africa, and Southeast Asia are missing, and perspectives from the pharmaceutical industry are largely absent. This limits the ability to generalise the findings or present them as a global picture. Response: As mentioned in our limitation section, more participants were approached but due to lack of consent, we could not interview them. This was not a global study with participants from all countries. Comment: The PESTELI framework offers structure for analysis, but the study remains descriptive and exploratory. Some of the conclusions read as prescriptive and definitive when they should be framed more cautiously. In addition, the ecological dimension of shortages was not explored, despite its importance in antibiotic manufacturing and the potential link to antimicrobial resistance in the environment. Response: We have modified the conclusion section. Due to the lack of evidence from the systematic review on the ecological impact of antibiotic shortages we did not explore this domain and allowed for the study participants to bring this up in the conversation. Additionally, our participants did not provide any information on this element. Comment: Another issue is novelty. The authors recently published a systematic review on antibiotic shortages, and the present work risks being seen as incremental rather than substantially new. The overlap between the two outputs should be made very clear. Response: The systematic review and this study are both part of the same research project. Hence our intention through these interviews were to collect more in-depth data. Comment: On balance, I believe the paper has potential value as a situational analysis of supply chain perspectives, but in its current form it does not make a sufficiently strong or novel contribution to merit indexing. Response: We have modified the paper to say that the aim is to do a situational analysis using key informant interviews with actors actively involved nationally and globally in antibiotic supply chain management to explore the main drivers for current shortages, existing mitigation strategies undertaken in different regions and potential barriers in their implementation. This is a timely and highly relevant study, which addresses a key challenge for healthcare systems around the world, namely antibiotic shortages. The paper offers a broad and variegated picture of the issue at hand, with the merit of representing several countries with a global spread. The authors followed a systematic approach and offer a clear narrative, building on sufficient first-hand empirical materials. They also rely on a relevant conceptual framing around PESTELI (with risk however of ending up being a bit superficial in the results that can be reported, due to the many dimensions to be covered within this framework). Previous works in this area are generally identified and accounted for. This paper has the potential to offer an important contribution to the topic of antibiotic shortages, but it also presents some issues that would need to be addressed to make it more clear and impactful. Below here comes a set of suggestions for developing and improving the study. Suggestions for improvements: -Despite a brief mention on page 2 (“explore the main drivers for current shortages and existing mitigation strategies”), the purpose and focus of the paper is not entirely clear: is it about categorizing (around PESTELI) the causes of shortages, potential policies against them or barriers to introducing these policies, only some of these elements or all of them? -While the application of the PESTELI framework certainly makes sense, the authors should explain why they have chosen it, for instance by mentioning the fact that there are many different causes of shortages and potential responses to address them, which include elements of the dimensions included in the PESTELI framework. An alternative approach of focussing for instance only on selected dimensions, such as the economic or political ones, could have also been weighed against the approach chosen in terms of pros and cons. -There is a clear unbalance among sampled experts towards South Africa. Can you please explain why as many as 8 out of 16 respondents were selected from this country, as well as which implications this potential bias have on the study’s results? -The logic for sampling respondents from the five selecting countries (+EU level), which are then even used as mini-cases in table 2, needs to be explained. Does it have to do with differences in healthcare systems, national income levels, policies to address antibiotic shortages? -It is clearly important to consider the geographic spread of respondents, as different countries face different challenges in improving access to antibiotics and different specific causes of shortages, suggesting consequently also different interventions for specific countries. While the geographic origins of respondents is accounted for in the paper, it would be equally important to know which sector the various experts represent, for instance, industry, healthcare professionals, policy/public authorities and academia, because stakeholders from these different sectors perceive the problem of shortages from different perspectives and have indeed different interests, motivations and available strategies to deal with shortages. -It would be useful to know what type of antibiotic shortages the paper focuses on, considering in particular short vs long-term and deregistration vs lack of registration. In fact, different types of shortages (or lack of access) have different causes and can be addressed through different policies (see [Reference 1]). -The structure of the results section is not easy to grasp, and is not explained at its very start, making it difficult for readers to follow the logic of arguments, except after the PESTELI framework is explicitly applied from the bottom of page 5. Readability would increase with a clear explanation of the structure and contents at the very start of the result section. Moreover, it is not clear why the section starts with discussing the differences between the five countries in focus, followed by causes of shortages at a general level. Probably, inverting these two first sub-sections would make more sense, as the logic flow would go from global items to country-specific ones. Moreover, as it stands now, Table 2, including details about the five selected countries provides many details which are actually already about policies to address and handle shortages or lack of access, making further sense to present these after the sub-section about causes of shortages. -It is not clear why certain causes of shortages shown on Figure 1 have been attributed to a specific dimension of PESTELI. For instance, why is “transporting and assembling to a final product” part of the sociological/ecological area? This factor seems more a technological or industry issue. Similarly, the “mismatch demand-supply” seems more an economic or industry issue than a sociological/ecological one: for instance, a small country’s yearly demand of a specific antibiotic may be smaller in volume than the size of a production batch, requiring several years before that country consumes the allocated volumes. “Hoarding behaviour” would deserve in my view a special place among the sociological dimensions on Figure 1, as it is also mentioned in the text on page 8/9. -It is not clear if the various subsections featuring the PESTELI elements concern causes of shortages or policies to address them, and to what extend the differences between the 5 case countries are considered. In fact, there is some inconsistency and lack of balance as to how much of causes, policies and country differences are considered under the various PESTELI sub-headings. Some of these sub-headings even considers consequences of shortages (e.g., the sociological one), an element which does not seem to be part of the purpose/scope of the paper. All in all, a more consistent structure and balance in the space dedicated to causes, followed by policies and country differences would make it easier to follow these parts of the results section. -Legal elements appear in the headings of both the first and a subsequent PESTELI sub-heading in the result section. Are the latter “legal factors” as opposed to “legal frameworks” referring to different issues? -As for “Industry factors”, the starting sentence “By and large, the role of industry is absent as an active partner in working to mitigate shortages.” may apply to South Africa and India, but certainly not to Sweden and possibly not to UK and USA, where industry is mandated to at the very least report upcoming shortages. -It is not clear which role is played by Figure 2 and the very last sub-section of the result section (Mitigation strategies…). The previous sub-sections have already presented various strategies and policies, classified according to PESTELI. So, why do we need an additional sub-section about policies at the very end of the result section? -Discussion: It is a bit surprising that a key point made at the start of this section is about a very specific and ambitious policy intervention such as “pooled procurement”, which was basically not mentioned in the result section. If it is so important, it should have been presented among the results, ideally as a legal and economic item according to the PESTELI framework. -Conclusions: this section is rather short and general, which does not match the richness and depth of the study. Ideally, this section could stress the key findings of the study and what makes it particularly useful, namely its unique contribution to the issue of antibiotic shortages. Minor issues: -The paper would benefit from proof-reading as it includes a few grammatical inconsistencies that should be amended. For instance: “a global shortages crises” (bottom of page 2); or “Current nationally available data resources on status of or respond to shortages” (heading of Table 2); “…whilst government is invested in supporting…” (bottom of page 5); or “…may be therefore have its limitations” (bottom of page 8). -As for Sweden, Table 2 should mention in the right-most column that, similarly to UK and US, the Swedish Medical Product Agency runs a constantly updated list of drugs in shortages, and for antibiotics they also gather an expert group of ID specialists to propose alternative antibiotics in case of shortages. -Again for Sweden, the following sentence is not correct: “Swedish model aims to generate additional manufacturer revenue to maintain the supply chain of five selected antimicrobials” (page 8), because this new payment model aimed to stimulate the registration in Sweden of 5 new antibiotics still protected by exclusivity, not to improve or maintain their supply chain. I hope these comments can help the author further develop their paper. References: [Reference 1] Is the work clearly and accurately presented and does it cite the current literature? Yes If applicable, is the statistical analysis and its interpretation appropriate? Not applicable Are all the source data underlying the results available to ensure full reproducibility? Yes Is the study design appropriate and is the work technically sound? Yes Are the conclusions drawn adequately supported by the results? Partly Are sufficient details of methods and analysis provided to allow replication by others? Yes Reviewer Expertise: Industrial engineering and management, marketing, industrial and innovation policy I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Comment: This is a timely and highly relevant study, which addresses a key challenge for healthcare systems around the world, namely antibiotic shortages. The paper offers a broad and variegated picture of the issue at hand, with the merit of representing several countries with a global spread. The authors followed a systematic approach and offer a clear narrative, building on sufficient first-hand empirical materials. They also rely on a relevant conceptual framing around PESTELI (with risk however of ending up being a bit superficial in the results that can be reported, due to the many dimensions to be covered within this framework). Previous works in this area are generally identified and accounted for. Response: The authors thank the reviewer for highlighting the relevance of the study. Comment: This paper has the potential to offer an important contribution to the topic of antibiotic shortages, but it also presents some issues that would need to be addressed to make it clearer and more impactful. Below here comes a set of suggestions for developing and improving the study. Response: We have responded point by point to the comments and have made the recommended changes to the manuscript. Comment: Suggestions for improvements: -Despite a brief mention on page 2 (“explore the main drivers for current shortages and existing mitigation strategies”), the purpose and focus of the paper is not entirely clear: is it about categorizing (around PESTELI) the causes of shortages, potential policies against them or barriers to introducing these policies, only some of these elements or all of them? Response: The aim of the study was to conduct a situational analysis using key informant interviews with actors actively involved, nationally and globally, in antibiotic supply chain management to explore the main drivers for current shortages, existing mitigation strategies undertaken in different regions and potential barriers in their implementation. We have added this as the aim consistently across the manuscript. Comment: While the application of the PESTELI framework certainly makes sense, the authors should explain why they have chosen it, for instance by mentioning the fact that there are many different causes of shortages and potential responses to address them, which include elements of the dimensions included in the PESTELI framework. An alternative approach of focussing for instance only on selected dimensions, such as the economic or political ones, could have also been weighed against the approach chosen in terms of pros and cons. Response: We have further clarified why the PESTELI framework was used in lines 171-176. Comment: There is a clear unbalance among sampled experts towards South Africa. Can you please explain why as many as 8 out of 16 respondents were selected from this country, as well as which implications this potential bias have on the study’s results? Response: Participation in the interview was voluntary. We reached out to stakeholders in South Africa, Europe, India and the USA and interviewed participants who consented. We have discussed the limitation this poses to the study. Comment: The logic for sampling respondents from the five selecting countries (+EU level), which are then even used as mini-cases in table 2, needs to be explained. Does it have to do with differences in healthcare systems, national income levels, policies to address antibiotic shortages? Response: Our intention was to include perspectives and experiences from different income setting countries/regions. This follows on from our systematic review, referenced in our manuscript which highlights that the published evidence from shortages comes mainly from high income countries. Comment: It is clearly important to consider the geographic spread of respondents, as different countries face different challenges in improving access to antibiotics and different specific causes of shortages, suggesting consequently also different interventions for specific countries. While the geographic origins of respondents is accounted for in the paper, it would be equally important to know which sector the various experts represent, for instance, industry, healthcare professionals, policy/public authorities and academia, because stakeholders from these different sectors perceive the problem of shortages from different perspectives and have indeed different interests, motivations and available strategies to deal with shortages. Response: Thank you for this comment. We have added another column to table 1 to include the sector where the interview participants work. Comment: It would be useful to know what type of antibiotic shortages the paper focuses on, considering in particular short vs long-term and deregistration vs lack of registration. In fact, different types of shortages (or lack of access) have different causes and can be addressed through different policies (see [Reference 1]). Response: We discussed in our interview guide shortages of licensed antibiotics. We have clarified this. Comment: The structure of the results section is not easy to grasp, and is not explained at its very start, making it difficult for readers to follow the logic of arguments, except after the PESTELI framework is explicitly applied from the bottom of page 5. Readability would increase with a clear explanation of the structure and contents at the very start of the result section. Moreover, it is not clear why the section starts with discussing the differences between the five countries in focus, followed by causes of shortages at a general level. Probably, inverting these two first sub-sections would make more sense, as the logic flow would go from global items to country-specific ones. Moreover, as it stands now, Table 2, including details about the five selected countries provides many details which are actually already about policies to address and handle shortages or lack of access, making further sense to present these after the sub-section about causes of shortages. Response: We have restructured the manuscript and added more detail, including justification for PESTELI, in line with the reviewer’s comment. Comment: It is not clear why certain causes of shortages shown on Figure 1 have been attributed to a specific dimension of PESTELI. For instance, why is “transporting and assembling to a final product” part of the sociological/ecological area? This factor seems more a technological or industry issue. Similarly, the “mismatch demand-supply” seems more an economic or industry issue than a sociological/ecological one: for instance, a small country’s yearly demand of a specific antibiotic may be smaller in volume than the size of a production batch, requiring several years before that country consumes the allocated volumes. “Hoarding behaviour” would deserve in my view a special place among the sociological dimensions on Figure 1, as it is also mentioned in the text on page 8/9. Response: We have modified figure 1 to address this comment. Comment: It is not clear if the various subsections featuring the PESTELI elements concern causes of shortages or policies to address them, and to what extend the differences between the 5 case countries are considered. In fact, there is some inconsistency and lack of balance as to how much of causes, policies and country differences are considered under the various PESTELI sub-headings. Some of these sub-headings even considers consequences of shortages (e.g., the sociological one), an element which does not seem to be part of the purpose/scope of the paper. All in all, a more consistent structure and balance in the space dedicated to causes, followed by policies and country differences would make it easier to follow these parts of the results section. Response: We acknowledge this variation in our findings and we interpret it as the complexity and diversity of issues that impact of antibiotic shortages in different countries. Comment Legal elements appear in the headings of both the first and a subsequent PESTELI sub-heading in the result section. Are the latter “legal factors” as opposed to “legal frameworks” referring to different issues? Response We have edited the sub heading to address this comment. Comment: As for “Industry factors”, the starting sentence “By and large, the role of industry is absent as an active partner in working to mitigate shortages.” may apply to South Africa and India, but certainly not to Sweden and possibly not to UK and USA, where industry is mandated to at the very least report upcoming shortages. Response: We made this point based on the data we collected through our interviews. Since there was a lack of participation from the pharmaceutical industries, we could not explore these further. Comment: It is not clear which role is played by Figure 2 and the very last sub-section of the result section (Mitigation strategies…). The previous sub-sections have already presented various strategies and policies, classified according to PESTELI. So, why do we need an additional sub-section about policies at the very end of the result section? Response: In addition to the mitigation strategies elaborated under the various elements of PESTELI in the results, the interview participants also provided some potential strategies to better handle situations of antibiotic shortages which are shown in Figure 2. Comment: Discussion: It is a bit surprising that a key point made at the start of this section is about a very specific and ambitious policy intervention such as “pooled procurement”, which was basically not mentioned in the result section. If it is so important, it should have been presented among the results, ideally as a legal and economic item according to the PESTELI framework. Response: We have discussed about pooled procurement under Results in lines 238-241. Comment: Conclusions: this section is rather short and general, which does not match the richness and depth of the study. Ideally, this section could stress the key findings of the study and what makes it particularly useful, namely its unique contribution to the issue of antibiotic shortages. Response: The conclusion section has been modified in response to this comment. Comment: Minor issues: -The paper would benefit from proof-reading as it includes a few grammatical inconsistencies that should be amended. For instance: “a global shortages crises” (bottom of page 2); or “Current nationally available data resources on status of or respond to shortages” (heading of Table 2); “…whilst government is invested in supporting…” (bottom of page 5); or “…may be therefore have its limitations” (bottom of page 8). Response: The authors thank the reviewer for pointing these errors. We have corrected them in the manuscript. Comment: As for Sweden, Table 2 should mention in the right-most column that, similarly to UK and US, the Swedish Medical Product Agency runs a constantly updated list of drugs in shortages, and for antibiotics they also gather an expert group of ID specialists to propose alternative antibiotics in case of shortages. Response: We have consulted the Swedish Medical Product Agency website and found a search engine that provides Information about reported medicine shortages. We have provided information regarding this in table 3. We could not find any details on the expert group of ID physicians. Comment: Again, for Sweden, the following sentence is not correct: “Swedish model aims to generate additional manufacturer revenue to maintain the supply chain of five selected antimicrobials” (page 8), because this new payment model aimed to stimulate the registration in Sweden of 5 new antibiotics still protected by exclusivity, not to improve or maintain their supply chain. Response: This is the quote verbatim from a participant. We cannot change it. We have provided context for this, in line with the advice from this comment.